Skip to content

Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site

Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04880603
Enrollment
5
Registered
2021-05-11
Start date
2021-04-05
Completion date
2022-04-25
Last updated
2022-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Brief summary

Adult patients undergoing a radial forearm free flap or ulnar forearm free flap will be randomized to the use of the Restrata graft in combination with split-thickness skin graft for reconstruction. Photos will document whether the Restata graft aids in the healing.

Interventions

DEVICERestrata Graft

Restrata will be meshed in a 1:2 fashion to allow for egress of serous fluid and minimize risk of fluid collection. Restrata will be applied to the entire wound bed not amenable to primary closure and will be underlaid beneath the surrounding skin edges. A split-thickness skin graft is harvested from patient's thigh at 15:1000 inches and placed on top of the Restrata to cover the entire wound bed. The graft is sutured in place using suture choice of surgeon's preference.

PROCEDUREStandard of Care Skin Graft

Standard of Care Skin Graft

Sponsors

Acera Surgical, Inc.
CollaboratorINDUSTRY
Nebraska Methodist Health System
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients age 19 or greater that will undergo radial forearm free flap or ulnar free flap. * Photo documentation of wound bed at two weeks and four weeks must be obtainable either by physician or patient.

Exclusion criteria

* Active systemic immunosuppression (active use of high-dose steroids (≥40mg prednisone daily or equivalent) or other immunosuppressive medications OR medical conditions causing immunosuppression, i.e. human immunodeficiency virus etc). * Diabetes mellitus with most recent Hemoglobin A1c ≥10.0 within 30 days prior to surgery. * Morbid obesity (BMI \>40). * Inability to maintain wrist immobilization for full planned period. * Severe malnutrition (prealbumin levels \<10 mg per dL within 30 days prior to surgery OR BMI \<15 (very severely underweight). * Other conditions felt to significantly impair wound healing per surgeon discretion

Design outcomes

Primary

MeasureTime frameDescription
Tendon exposure4 weeks post-operationTendon exposure at four weeks post-operatively (Yes/No).
Percentage of surface area4 weeks post operationPercentage of surface area of split-thickness skin graft incorporation at four weeks postoperatively.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026